0 prosjekter

BEDREHELSE-Bedre helse og livskvalitet

Turning the wastewater pitfall source of antimicrobial resistance and antibiotics into a re-constituted One Health benefit

The purpose of the AMR-1 project is to monitor and clean the wastewater from main hospitals in Norway and Sweden. The Oslo University Hospital represents a major source of bacteria and other microbes carrying AMR determinants. In addition, a lot of drugs including antibiotics are emitted into the...

Tildelt: kr 0,20 mill.

Prosjektperiode: 2021-2022

Sted: Oslo

PES-HORISONT-EU-PES Horisont Europa

MicroFuel as Aviation Fuel - From waste to wing

The need for low-cost biofuels and bio-products from sustainable renewable resources is rapidly increasing. Higher chain alcohols (C5–C8) are vital because they are important as chemical feedstock as well as efficient biofuels. Higher chain alcohols are not known to accumulate in substantial amou...

Tildelt: kr 99 999

Prosjektperiode: 2021-2022

Sted: Oslo

INTPART-International Partnerships for Excellent Education and Research

Reversing antimicrobial resistance (AMR)

Antimikrobiell resistens (AMR) er en global helsetrussel, både hos mennesker og dyr. Denne situasjonen har eskalert globalt og nasjonalt de siste årene, og har blitt en av verdens store pandemier. Verdens helseorganisasjon (WHO) har laget en prioritetsliste over de viktigste globale sykdomsfremka...

Tildelt: kr 3,5 mill.

Prosjektperiode: 2020-2023

Sted: Oslo

JPIAMR-JPI Antimikrobiell resistens

Development of novel Mycobacterial Tolerance Inhibitors (MTIs) against MDR/XDR tuberculosis

Mycobacterium tuberculosis (Mtb) er årsaken til den alvorlige sykdommen tuberkulose (TB). Multi-resistent Mtb er en hovedsak på WHOs liste over de viktigste globale sykdomsfremkallende mikrobene. Listen er utarbeidet for å fremme forskning og utvikling av ny behandling mot multi-resistente mikrob...

Tildelt: kr 5,8 mill.

Prosjektperiode: 2019-2022

Sted: Oslo

BIOTEK2021-Bioteknologi for verdiskaping

Conference: "5th Genome Maintenance Meeting / 3rd Turning the Tide of Antimicrobial resistance meeting" (GMM5/TTA3)

In this joint conference "5th Genome Maintenance Meeting” / 3rd Turning the Tide of Antimicrobial resistance (AMR) meeting" (GMM5/TTA3), we will focus on genome dynamics, AMR and new drug design. The GMM5 / TTA3 meeting will highlight recent progress in the understanding of how DNA transfer pathw...

Tildelt: kr 99 999

Prosjektperiode: 2018-2019

Sted: Oslo

BEDREHELSE-Bedre helse og livskvalitet

Antimicrobial resistance - network on chromosomally-mediated resistance

Overforbruk av antibiotika har ført til at mange bakterier har blitt motstandsdyktige mot denne medisinen. Antimikrobiell resistens (AMR) er en enorm belastning for helsevesenet og samfunnsøkonomien og truer både lokal og global helse. Dette ønsker AMR-CHROM å gjøre noe med. AMR-CHROM har derfor ...

Tildelt: kr 1,00 mill.

Prosjektperiode: 2017-2019

Sted: Oslo

INTPART-International Partnerships for Excellent Education and Research

Reversing antimicrobial resistance

Antimikrobiell resistens (AMR) er en global helsetrussel, både hos mennesker og dyr. Denne situasjonen har eskalert globalt og nasjonalt de siste årene Vi har derfor utviklet en INTPART strategi med forskningsbasert undervisning og avansert opplæring for å sikre innovativ forebyggelse, diagnostik...

Tildelt: kr 4,5 mill.

Prosjektperiode: 2017-2019

Sted: Oslo

GLOBVAC-Global helse- og vaksin.forskn

Impact of Mycobacterium tuberculosis exosomes

Tuberkulose (TB) er en av de 10 mest dødelige sykdommene på verdensbasis. Tuberkulosebakterien finnes hos circa 1/3 av jordens befolkning, og 9 millioner nye TB-tilfeller påvises årlig. Den pågående epidemien blir forverret av antibiotika-resistente varianter av bakterien Mycobacterium tuberculos...

Tildelt: kr 8,8 mill.

Prosjektperiode: 2014-2020

Sted: Oslo

GLOBVAC-Global helse- og vaksin.forskn

GMMnet: Genome Maintenance Meeting-based network

GMMnet Aim and Scope: The stability of microbial genomes and gene pools will constantly be challenged by horizontal gene transfer and recombination, as well as DNA damage induced by endogenous as well as exogenous agents. Mechanisms for rapid genome varia tion, adaptation and maintenance are a ne...

Tildelt: kr 0,30 mill.

Prosjektperiode: 2013-2014

Sted: Oslo

BIOTEK2021-Bioteknologi for verdiskaping

The 4th Genome Maintenance Meeting (GMM4)

The 4th Genome Maintenance Meeting lasts from April 26 until April 29, 2013. 39 internationally recognized scientists from all over the world have confirmed their attendance as speakers. This is the fourth in line of a series of successful international m eetings, addressing genome instability an...

Tildelt: kr 0,15 mill.

Prosjektperiode: 2013-2013

Sted: Oslo

GLOBVAC-Global helse- og vaksin.forskn

Genetically engineered N. lactamica as a vaccine delivery agent

Neisseria meningitidis (Nm) er en bakterie i normal halsflora som kan spre seg i kroppen og forårsake alvorlig blodforgiftning og hjernehinnebetennelse, spesielt hos små barn og tenåringer. Selv om vaksiner er underveis, oppstår det stadig nye farlige Nm-varianter. Det er derfor et stort behov fo...

Tildelt: kr 7,0 mill.

Prosjektperiode: 2013-2020

Sted: Oslo

BIOTEK2021-Bioteknologi for verdiskaping

The 4th Genome Dynamics in Neuroscience Meeting

This year's Genome Dynamics in Neuroscience conference lasts from September 19 until September 22. 42 internationally recognized scientists from all over the world have confirmed their attendance as speakers, and there will be room for over 100 additiona l participants. This is the fourth in lin...

Tildelt: kr 0,20 mill.

Prosjektperiode: 2012-2012

Sted: Oslo

FRIMEDBIO-Fri prosj.st. med.,helse,biol

Small RNAs and DNA repair in Mycobacterium tuberculosis adaptive responses

Tuberkulose (TB) er en av verdens mest utbredte infeksjoner, som tar nesten 1.3 millioner liv og forårsaker 8.7 millioner infeksjonstilfeller årlig. Årsaken er Mycobacterium tuberculosis (Mtb), som infiserer 1/3 av verdens befolkning og har forårsaket flere dødsfall enn noen annen mikrobe. Behand...

Tildelt: kr 3,8 mill.

Prosjektperiode: 2011-2014

Sted: Oslo

GLOBHELS-Global helse

Novel vaccine candidates against meningococcal disease

Meningococcal disease is a leading cause of meningitis and septicaemia globally, most often striking small children and teenagers. Due to the lack of efficient vaccines, serogroup B meningococcal disease is currently emerging on a worldwide basis. The rat ional design of outer membrane protein-ba...

Tildelt: kr 4,0 mill.

Prosjektperiode: 2010-2013

Sted: Oslo

IS-BILAT-Mobilitet Norge-USA /Canada

Genome dynamics and adaptation in Mycobacterium tuberculosis

Tuberculosis (TB) remains a major public health threat, still emerging in many parts of the world. The burden of TB has been further exacerbated by the synergistic effect of HIV and consequently TB has become the most common cause of the death among HIV- infected adults in developing countries. ...

Tildelt: kr 97 000

Prosjektperiode: 2009-2009

Sted: Oslo

FRIMEDBIO-Fri prosj.st. med.,helse,biol

Neurogenetics of aging: impact of DNA repair on Alzheimer disease

The genetic background for cognitive loss, dementia and aging processes is poorly described, and multidisciplinary research is needed to increase this knowledge. Alzheimer disease (AD) is by far the most important contributor to cognitive decline and deme ntia worldwide. Incidence may quadruple s...

Tildelt: kr 4,1 mill.

Prosjektperiode: 2009-2013

Sted: Oslo

FRIMEDBIO-Fri prosj.st. med.,helse,biol

Cellular responses to meningococcal meningitis

Meningococcal disease is a leading cause of meningitis and septicaemia worldwide. Among the serious consequences of meningitis are brain edema and disturbed neuronal excitability. These effects are often the direct cause of death. Despite the serious comp lications, the molecular basis for these ...

Tildelt: kr 3,4 mill.

Prosjektperiode: 2007-2012

Sted: Oslo

SFF-Sentre for fremragende forskn

Center of Molecular Biology and Neuroscience, CMBN/Senter for molekylærbiologi og nevrovitenskap

The treatment of brain diseases continues to lag behind the treatment of disease in other fields of medicine. New principles for therapy and new drug targets are urgently needed. CMBN aims at identifying new directions for therapy through a multidisciplin ary investigation of relevant biological ...

Tildelt: kr 210,0 mill.

Prosjektperiode: 2002-2013

Sted: Oslo

GNBIO-Grunnleggende næringsrettet bioteknologi

Molecular mechanisms of natural transformation: impact on virulence and genome variability in the pneumococcus and the pathogenic Neisseria

...

Tildelt: kr 4,2 mill.

Prosjektperiode: 2002-2006

Sted: Oslo

AB-MED1-Basal medisinsk forskning I

Dissemination of antibiotic resistance determinants by horizontal gene transfer/natural genetic transformation

...

Tildelt: kr 1,5 mill.

Prosjektperiode: 2001-2005

Sted: Oslo

MHGRUPP2-MH-grupper

Genome stability and repair

...

Tildelt: kr 13,0 mill.

Prosjektperiode: 2001-2006

Sted: Oslo